Hims & Hers Delivers Huge Growth Despite Stock Drop

Hims & Hers - our best performing pick ever - reported another outstanding quarter and fiscal year. For the year, revenues were up 69%, with Q4 coming in 95% higher than the comparable quarter last year - its fastest growth quarter of the year. The company has a lot of momentum. Monthly revenue per subscriber was up 19% of the year, 38% for the quarter. HIMS ended the year with 2.2 million subscribers, a 45% increase over last year. Yes, I know the stock has plummeted from $70 down to the low $40's, but the $70 number was just market foolishness over GLP hype. The truth is that less than 15% of Hims & Hers business is GLP drugs, and the company grew revenue 43% even taking that out entirely. With my new (and greatly raised) $35 price target, where it trades now is approaching fair value. This is going to be a wild ride, and my plan is to just ride it out. The trajectory should be up - way up - over time. Let your winners ride!

Watch List

APPF 4.30%
CMG 40.33%
PSTG -1.39%
WDAY -5.41%
VEEV 19.23%
INTU 20.20%
RDDT 16.57%
NTNX 27.22%
CRWD 95.83%
SE 32.72%
SNOW 13.92%

Buy List

PINS -38.24%
SEMR -33.68%
TSM -40.25%
ZETA -27.44%
GOOG -50.34%
NYAX -30.24%
MSFT -28.00%
FLYW -39.29%
HRMY -59.63%
YOU -39.80%
ABNB -31.51%
ADBE -41.68%

Hold List

ASML -23.91%
VTEX -13.76%
ODD -6.91%
ASR -24.09%
CELH 39.84%
TOST 18.60%
CPNG -11.81%
HIMS -5.43%
PAYC -18.56%
MNDY 21.64%
GLBE -21.93%
ZS 38.75%
V -4.82%
ADSK 1.57%
NOW 15.34%
MELI -19.68%
FTNT 1.73%
TEAM 0.14%